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A new methodology using hydrogen/deuterium amide exchange (HDX) to determine the
binding affinity of protein-peptide interactions is reported. The method, based on our
previously established approach, protein ligand interaction by mass spectrometry, titration,
and H/D exchange (PLIMSTEX) [J. Am. Chem. Soc. 2003, 125, 5252–5253], makes use of a
dilution strategy (dPLIMSTEX) for HDX, using the mass of the peptide ligand as readout. We
employed dPLIMSTEX to study the interaction of calcium-saturated calmodulin with the
opioid peptide -endorphin as a model system; the affinity results are in good agreement with
those from traditional PLIMSTEX and with literature values obtained by using other methods.
We show that the dPLIMSTEX method is feasible to quantify an antigen-antibody interaction
involving a 3-nitrotyrosine modified peptide in complex with a monoclonal anti-nitrotyrosine
antibody. A dissociation constant in the low nanomolar range was determined, and a binding
stoichiometry of antibody/peptide of 1:2 was confirmed. In addition, we determined that the
epitope in the binding interface contains a minimum of five amino acids. The dPLIMSTEX
approach is a sensitive and powerful tool for the quantitative determination of peptide affinities
with antibodies, complementary to conventional immuno-analytical techniques. (J Am Soc Mass
Spectrom 2010, 21, 1660–1667) © 2010 American Society for Mass SpectrometryProtein-peptide interactions are important in basicbiophysics and in research aimed at developmentof therapeutic agents. Antibody-antigen binding
affinity and specificity are of special interest; they are
essential aspects in immune function investigation, as-
say development, biomarker discovery, and rational
drug or vaccine design [1, 2]. Affinity determination of
antibody-peptide interactions is key to characterize
recognition specificities of antibodies, to delineate the
antigenic determinant (epitope mapping) [3, 4], and to
probe the antibody-binding ability of synthetic peptides
derived from the amino acid sequence of the antigen
protein when the epitope is linear or continuous [2, 5].
Binding affinity has been typically assessed by using
enzyme-linked immunosorbent assay (ELISA), surface
plasmon resonance (SPR) including Biacore, and iso-
thermal calorimetry [1].
The advantages of a mass-spectrometry-based ap-
proach for measuring binding constants of protein-
ligand systems include high accuracy, high sensitivity,
and straightforward data analysis [6, 7]. Many MS
methods employ hydrogen/deuterium amide exchange
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doi:10.1016/j.jasms.2010.03.030(HDX), which also has been widely used to determine
protein conformations, binding interfaces, and dynam-
ics [8–10]. Stability of unpurified proteins from rates of
H/D exchange (SUPREX) makes use of the extent of
protein HDX in various concentrations of denaturants
to determine the affinities of protein-ligand complexes
[11–19]. Stability of proteins from rates of oxidation
(SPROX) takes a similar approach, adopting hydrogen
peroxide-mediated methionine oxidation instead of HDX
as the readout [20]. Protein-ligand interaction by mass
spectrometry, titration, and H/D exchange (PLIMSTEX),
previously developed in the Gross laboratory, tracks
changes in the extent of protein HDX at various ligand/
protein ratios to give affinity, stoichiometry, and confor-
mational changes that occur upon ligand binding [21–25].
Thus far, there are no reports of extending theseMS-based
methods to antibody-antigen binding.
Nevertheless, HDX is effective for epitope mapping
to probe antibody-antigen interactions [2, 26–30]. HDX
takes advantage of the drastically slower kinetics of
HDX rates in regions of an antigen shielded by binding
with an antibody [2, 28–30]. In many cases, HDX results
are combined with affinity measurements from SPR to
obtain more certain epitope delineation [27, 29, 30].
Here we report a novel adaption of PLIMSTEX by
incorporating a dilution strategy, dPLIMSTEX, for affin-
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sign goal of the dilution strategy is to minimize protein
consumption in the measurement. In addition, unlike
traditional PLIMSTEX that monitors the protein mass as
HDX occurs, dPLIMSTEX uses HDX of the ligand
peptide as readout. Given that the mass of the peptide
is more readily measured than that of the antibody, the
approach should add precision and accuracy to the
determination of antibody-peptide affinities. Moreover,
with dPLIMSTEX, the problems of low ionization effi-
ciency and relatively small and hard-to-measure
changes in mass of an antibody are avoided. The
approach also provides information on the minimum
number of amino acids constituting the epitope at the
binding interface.
Experimental
Materials
Porcine calmodulin (MW 16,790) was purchased from
Ocean Biologics Co. (Edmonds, WA, USA). The monoclo-
nal mouse anti-3-nitrotyrosine antibody (SC-Ab, 39B6)
was obtained from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA), and was raised against a 3-(2-(4-
hydroxy-3-nitrophenyl) acetamido)propionyl-bovine serum
albumin immunogen conjugate. -Endorphin, deuterium
oxide (D2O), formic acid (FA), hydrochloric acid (HCl),
calcium chloride (CaCl2), potassium chloride (KCl),
3-(N-morpholino)propanesulfonic acid (MOPS) hemiso-
dium salt, N-(2-hydroxyethyl)-1-piperazineethanesulfonic
(HEPES) acid, HEPES sodium salt were obtained from
Sigma-Aldrich (St. Louis, MO, USA). All reagents and
solvents were of analytical grade or highest available
purity.
Peptide Synthesis
The antigenic peptide, prostacyclin synthase (PCS) (79-91),
containing 3-nitrotyrosine [H-DPHS83Y(NO2)DAVVWEPR-
OH; PCS2a], was synthesized on a semi-automated pep-
tide synthesizer (EPS-221; Intavis, Langenfeld, Ger-
many) by solid-phase peptide synthesis (SPPS) with
Fmoc/t-butyl protection chemistry. The peptide was
purified by reversed-phase-high-performance liquid
chromatography (RP-HPLC), and its purity confirmed
by electrospray ionization mass spectrometry (ESI-MS).
HDX Protocol
Solutions of calmodulin saturated with calcium (CaM ·
4Ca2) and -endorphin were prepared in aqueous buffer
containing 200 mM KCl, 50 mM MOPS (pH 7.3), and 10
mM CaCl2. Solutions of anti-3-nitrotyrosine antibodies
and PCS2a were prepared in a buffer containing 150
mM KCl and 10 mM HEPES (pH 7.4). Protein-peptide
mixture solutions were incubated for 2 h at room
temperature to establish equilibrium before starting
HDX. To initiate the HDX, a solution of protein-peptidecomplex or peptide alone was mixed with an equal
volume of D2O buffer (with the same salt composition
as of the aqueous solution) at room temperature. After
65 s, the exchange was quenched by adding ice-cold HCl
solution (0.5 M) to afford a final pH of 2.5, and the
sample was quickly frozen in liquid nitrogen until desalt-
ing and analysis. For the -endorphin:CaM system, both
traditional PLIMSTEX and the new dPLIMSTEX were
performed to permit comparison; a C18 guard column
was used for desalting, as described previously [21, 22,
25]. For the antibody-peptide system, C18 ziptips (Mil-
lipore, Billerica, MA, USA) were used to desalt the
antigenic peptide. After the frozen sample was removed
from the liquid nitrogen, introduction to the ziptip was
initiated when half the volume of the sample was
melted and the other half remained frozen. The ziptip
procedures were performed with ice-cold solvents
within 30–50 s to minimize back-exchange. The de-
salted peptide solution was immediately injected into
the mass spectrometer through a steel T-union (Cobert
Associates, St. Louis, MO, USA) that was connected
with an isocratic LC flow of 50% acetonitrile containing
0.1% formic acid at 40 L/min. The T-union and the
capillaries for the LC and mass spectrometer connec-
tions were placed in an ice bath. HDX of the free
peptide using the ziptip desalting method was per-
formed to determine the back-exchange extent of this
method. The HDX shift was compared with the theo-
retical number of exchangeable amide protons on the
peptide backbone, allowing us to deduce that the back-
exchange was below 20%. Free peptide HDX defined
the asymptote (D0, the mass of the free peptide after
HDX) in the data modeling; its determination acted as a
standard experiment that was performed daily to check
the experimental settings and to assist with trouble-
shooting when needed.
The adoption of C18 ziptips greatly facilitated pep-
tide desalting and concentrating in the case of antigen-
antibody complexes, given that the C18 column used
for traditional PLIMSTEX would easily get clogged by
injection of large antibody molecules. We found that
C18 guard columns quickly lost their efficiency for
peptide-binding and desalting after 1 to 2 injections of
an antibody-peptide mixture. To overcome this prob-
lem, antibody immobilization has been often effectively
employed, which enables the separation of antibody
by precipitation [26–28]; however immobilization ap-
proaches cannot be used in dPLIMSTEX as a solution
method. The use of C18 ziptips (200 Å pore size)
obviated the problem of a guard column and provided
efficient and reproducible desalting. Furthermore, the
ziptips were used only once and disposed, preventing
sample carryover. C4 ziptips (300 Å pore size) were also
evaluated, but with them, no or poor mass spectral
signal was seen for the peptide when its concentration
was comparable to that of the protein, probably because
the C4 ziptip had insufficient capacity to bind the
peptide in the presence of antibody.
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For -endorphin:CaM system, ESI mass spectra were
acquired in the positive-ion mode on a Micromass
Q-TOF Ultima (Waters, Manchester, UK) with a Waters
nanoAcquity UPLC, or on a LCQ Deca XP plus
(Thermo, San Jose, CA, USA) with a Waters CapLC
system (Manchester, UK). For the antibody-peptide
system, an LTQ Orbitrap XL (Thermo) was used for ESI
acquisition in the positive-ion mode. For the mea-
surements on the LTQ Orbitrap or LCQ Deca XP plus,
the spray voltage was 4.0 kV, and the capillary
temperature was 250 °C. The other instrument param-
eters were optimized based on the tuning for the most
abundant charge-state peak from the peptide of interest,
and the zoom scan mode was utilized. On the Q-TOF
instrument, the capillary voltage was 3.2 kV, and the
source and desolvation temperatures were 80 and
180 °C, respectively. The cone and desolvation gas
flows were 40 and 400 L/h, respectively.
Data Processing
The mass centroids of isotopic pattern envelops from
peptide mass spectra were calculated, and the data
were sorted into sets with each containing data from
experiments having the same macromolecule concen-
tration, MT. A modeling program implemented with
Mathcad V14_M020 professional (MathSoft, Inc., Cam-
bridge, MA, USA) was designed to fit all sets of data
with different MT and to extract Ka (affinity constant)
and D1 (difference in deuterium uptake between
bound and unbound state of the peptide). More details
are below.
Modeling Procedure
The process to quantify the affinity of antibody peptide
binding began with a plot of the peptide HDX mass
versus the ratio of total ligand concentration [LigT] to
the total macromolecule (protein) concentration [MT],
referred to as a dPLIMSTEX curve. The objective of the
process was to obtain the best-fit model curve to the
dPLIMSTEX data; from the best-fit curve were extracted
the binding constants and the changes in HDX that
occurred upon binding. For the general case of 1:n
protein:ligand binding model, where n is the number of
binding sites for the same ligand, these unknown pa-
rameters included the overall binding constants (i, i 
1 to n, which is the product of all the stepwise macro-
scopic binding constants Kj, j  1 to i), and ligand
deuterium shifts upon binding (Di, i  1 to n, which is
the difference between the average deuterated mass of
the bound ligand in the ith complex and that of the
apo-ligand form). Program components used for calcu-
lation of the solution equilibrium remained much the
same from previous implementations of PLIMSTEX
[23]: D0 is the HDX mass of the free peptide; [Lig] and
[M] represent free ligand concentration and free mac-romolecule concentration in the solution phase equilib-
rium, respectively.
In general, the most challenging task in the modeling
procedure was to establish the relationship between the
free solution ligand concentration [Lig] and the total
ligand concentration [LigT]. As we reported before [23],
[Lig] can be inferred from [LigT] by numerically solving
the ordinary differential equation formed by the ana-
lytical derivative of the solution ligand concentration
with respect to the total ligand concentration as shown
in eq 1 (0  1).
d[Lig]
d[LigT]
(1,...,n, [MT], [Lig], [LigT])


i0
n
i[Lig]
i
i0
n
(i 1)i[Lig]
i [MT] i1
n
i2i[Lig]
i1
 [LigT] i1
n
ii[Lig]
i1
(1)
In the case of 1:1 binding systems, eq 1 can be simplified
to give eq 2.
d[Lig]
d[LigT]
(Ka, [MT], [Lig], [LigT])

1Ka[Lig]
1 2Ka[Lig]Ka[MT]Ka[LigT]
(2)
The differential eq 1 or 2 was solved by integration from
the initial state of zero [Lig] at zero [LigT] by using the
“Rkadapt” function in Mathcad software. The integra-
tion produced a lookup table for the free ligand con-
centration as a function of the total ligand concentra-
tion; the table had a constant step size that resulted in
2000 intervals over the ligand range in the experiment.
Each experimental total ligand concentration value had
a matching value in the lookup table.
In addition to the solution-phase equilibrium as
modeled above, the model must also include the mass
shift signal function, which is a function different from
that used for PLIMSTEX. Because dPLIMSTEX uses the
peptide mass as readout for HDX, this function gave the
relationship for the average HDX mass of the ligand
peptide, D, which was expressed by the deuterium
shifts of the ligand molecules from each species, as
shown in eq 3.
DD0
i1
n
Di
ii[Lig]
i[M]
[LigT]
(3)
If [M] was expressed as a function of i, [Lig], and the
total macromolecule concentration [MT] using binding
polynomial, eq 4 can be derived from eq 3.
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[MT]
[LigT]

i1
n
Di
ii[Lig]
i
1
j1
n
j[Lig]
j
(4)
For a 1:1 binding system (i.e., n  1), i became the
affinity binding constant Ka. Correspondingly, eq 4 can
be converted to eq 5.
D(Ka,D0,D1, [LigT], [MT])
D0D1
[LigT] [Lig](Ka, [LigT], [MT])
[LigT]
(5)
Dilution data were sorted into sets with each containing
data from experiments having the same macromolecule
concentration [MT]. In each trial of the nonlinear least-
squares search (NLLS), a theoretical curve based on the
trial parameters was computed for each of the macro-
molecule concentrations, the squares of the residuals
between the corresponding data and the theoretical
curves for all the experiment ligand-macromolecule
concentration ratios were summed, and the square root
of the mean was taken for the value to be minimized.
Once a best-fit PLIMSTEX curve was obtained from
the process, the solution values of the unknown param-
eters (i and Di) and the deviation between the exper-
imental data and the fitted curve (RMS) were reported.
In most circumstances, multiple independent trials un-
der the same experimental conditions were performed
for each data point. A bootstrap resampling method
[31] was used to evaluate the precision of the solution
parameters. At each titration point, the data were
resampled by randomly selecting with replacement the
same number of times as the number of trials available
at that point. This was done for all the titration points to
form a “new” dataset. Rather than refitting each of a
large number of the new sample sets, each new set of
solution parameters was estimated to first-order by using
the residuals produced by the new samples. Second-order
statistics of the collection of new solution parameters were
computed as described previously [23].
Results and Discussion
Dilution Strategy for dPLIMSTEX
The efficiency of dPLIMSTEX stems from a procedure
whereby we used a fraction of the sample for measure-
ment. Instead of disposing of the unused portion, that
fraction was diluted and used again. In the typical
workflow of the dilution steps, a half volume of the
starting protein-peptide solution was equilibrated di-
rectly to form the complex, and the other half volume
was diluted by aqueous buffer before incubation (out-
lined in Scheme 1). The latter solution was further
divided and diluted by the same procedure. The dilu-
tion steps can be continued until the concentration of
the analyte becomes so low that it is no longer detect-
able by the mass spectrometer.As an illustration of the expected results from a
dPLIMSTEX approach, we used the modeling program
to generate a series of theoretical curves based on a 1:1
binding system with a specific Ka and D1 (Figure 1).
The upper horizontal line represents the value ofD0, the
free peptide mass after HDX determined without any
macromolecule present; this value is an average of
replicate measurements. The curves below correspond
to dilution series of different [MT] values, where [MT]
refers to the total concentration of the macromole-
cule, with a dilution factor of two (i.e., each curve
represents a 2-fold dilution from the curve immedi-
ately below it). When the [LigT]/[MT] ratio is low,
generally the dPLIMSTEX curves exhibit relatively
large slopes and curvatures, as shown in the shadowed
area (Figure 1) denoted as the “steep region”. The
curves become flat, and their slopes smaller in the “flat
region”, and they eventually approach the upper hori-
zontal line when the [LigT]/[MT] ratio reaches infinity.
Data distributed in the “steep region” are more sensi-
tive to changes of binding affinity and dilution factor,
thus carrying more information for determining fitting
parameters (Ka and D1). The data modeling outcomes,
Ka and D1, depend on the shape of the fitting curves
and the mass difference between data points; thus, it is
important to measure all the data points under the same
experimental conditions so that any inevitable back-
Scheme 1. Typical work flow for the dilution strategy used in
dPLIMSTEX. The terms x and y are the initial concentrations
(M) of protein and peptide, respectively, and z is the dilution
factor.exchange will be consistent for all the experiments.
1664 TU ET AL. J Am Soc Mass Spectrom 2010, 21, 1660–1667Application of dPLIMSTEX to a Model System
We chose calmodulin and its binding to -endorphin as
a model system to evaluate dPLIMSTEX and to com-
pare it with traditional PLIMSTEX. Calmodulin exhibits
high-affinity, calcium-dependent binding to several
peptide hormones and neurotransmitters [32–35]. -
Endorphin, an opioid peptide containing 32 amino
acids, binds calmodulin with a 1:1 stoichiometry and a
dissociation constant of 1.9–3.8 M (25 °C, pH 7.3) as
determined by fluorescence of dansylcalmodulin [32],
and of 2.5–4.6 M (4 °C, pH 7.0) as determined by
equilibrium dialysis [34].
Conventional PLIMSTEX yields a titration curve
(Figure 2a) that gives a binding constant (Ka) for
CaM · 4Ca2 and -endorphin of (2.2  0.1)  105 M1
(Kd  4.5  0.2 M), which agrees well with the
literature values [32, 34]. The D1 value is 15.0; given
that the D2O content is 50% for the HDX, there are 30
backbone amide protons of CaM · 4Ca2 that become
protected when binding to -endorphin. This number is
similar to that determined by PLIMSTEX for the inter-
action between CaM · 4Ca2 and melittin [21], suggest-
ing that similar conformational changes may occur
when calmodulin binds to each ligand [36].
The dPLIMSTEX fitting result, shown in Figure 2b,
affords a binding constant Ka of (2.05  0.09)  10
5 M1
(Kd  4.9  0.2 M), which is in good agreement with
both the result from traditional PLIMSTEX and those
from the literature [32, 34]. Although the curve fitting
Figure 1. A series of theoretical dPLIMSTEX curves generated
from the modeling program implemented in Mathcad. The curves
were calculated based on a 1:1 binding systemwith Ka 1 M and
D1  5 for illustration.seems to involve only a few data points, an importantand additional data point is D0 (the mass of the un-
bound -endorphin submitted to HDX in the same
media as for the complexes). Furthermore, this point is
an average value from repeated measurements of the
peptide (free -endorphin) mass after HDX. This is the
asymptote for the curves when [-endorphin]total/
[CaM · 4Ca2]total becomes infinite. The best-fitting
curves separate well from each other because the exper-
imental [CaM · 4Ca2] total values are close to Kd.
It should be emphasized that these three curves do
not represent separate fits. Rather, the curves arise in
the same model from the same fit parameter values (Ka,
D1). The curves are mutually dependent and simulta-
neously generated by themodeling procedure from fitting
all the eight data points in Figure 2b (at three different
[-endorphin]total/[CaM · 4Ca
2]total ratios) and the D0,
which is the asymptote. The deviation between the best-
fitted curves and the experimental data RMS is 0.061.
Thus, any conclusions that dPLIMSTEX uses a sparse
dataset should be reconsidered.
Figure 2. Traditional PLIMSTEX (a) and dPLIMSTEX (b) fitting
curves for CaM · 4Ca2: -endorphin. The error bars shown for
the data points represent the standard deviation from duplicate
independent experiments. The D0 point in (a), is a single point for
the apo state of the protein and also a “fit parameter”, whereas for
(b), the D mass is for the unbound peptide is depicted as a line0
representing the asymptote for the other curves in (b).
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which is a measure of the number of sites protected in
calmodulin by the binding, the D1 from dPLIMSTEX
reflects the number of protected amides on the peptide
and complements that from PLIMSTEX. The D1 ob-
tained by dPLIMSTEX is 3.96  0.09. Correcting for the
concentration of D2O (50%) in the exchange media, we
conclude that at least eight backbone amides from
-endorphin are protected upon binding to CaM · 4Ca2.
Comparing the sequence of -endorphin to that of other
calmodulin-binding peptides or proteins, Malencik and
Anderson [32] suggested that the active region of -
endorphin, containing about eight amino acids, is lo-
cated between a hydrophobic region and a basic region.
Using a series of amino- and carboxy-terminal deletion
peptides, Giedroc et al. [37] identified the residues
14–25 as the domain of -endorphin responsible for the
inhibition of calmodulin function.
The dilution approach employed in dPLIMSTEX al-
lows one to minimize the quantity of macromolecule used
in the determination for a certain system compared with
that used in traditional PLIMSTEX. For example, in the
dPLIMSTEX experiment shown in Figure 2b, eight data
points at three different [-endorphin]total/[CaM ·
4Ca2]total ratios were used, consuming 200 pmol of
protein for duplicate independent measurements. The
experiment shown in Figure 2a, however, consumed840
pmol of protein for duplicate determinations of 21 titra-
tion points. This latter quantity could be reduced to 480
pmol by using 12 titration points, which has been used for
1:1 binding in traditional PLIMSTEX [21, 22, 25]. Note that
these quantities are not absolute for a dPLIMSTEX
or traditional PLIMSTEX method; given that the
quantities are highly dependent on the affinity of the
target interaction system (the ideal condition to work
with in dPLIMSTEX is when the macromolecule con-
centrations are comparable to Kd value, as shown in
Figure 1). All the eight data points for dPLIMSTEX are
distributed in the “steep region” of the fitting curves,
where the data are more informative for the unknown
fitting parameters (Ka and D1) than those in the “flat
region”. Furthermore, given that the peptide is reporter
for dPLIMSTEX, only it, and not the protein, is con-
sumed in setting up and optimizing the mass spectro-
metric measurements.
Application to Peptide-Antibody Immune
Complexes
An application of dPLIMSTEX to peptide-antibody im-
mune complexes, explored here for the first time, aims
to characterize the recognition specificity of a monoclo-
nal antibody against the 3-nitrotyrosine peptide. A
Tyr-nitrated peptide of prostacyclin synthase (PCS) was
used as a model system for this application. In previous
work, it was shown that PCS in bovine aortic micro-
somes undergoes specific nitration upon treatment with
peroxynitrite at Tyr-430, as identified by high resolvingpower mass spectrometry [38]. To investigate the rec-
ognition specificities of 3-nitro-tyrosine antibodies, a
commercially available monoclonal antibody, SC-Ab
(39B6), was used. The interaction of the antibody with
PCS2a from PCS (79-91) in which Tyr-83 was nitrated
[38–40] was measured by dPLIMSTEX.
Typically, high affinity antibody (IgG type) antigen
interactions have Ka values in the range of 10
8–1010 M1
(dissociation constant Kd in the nanomolar (nM) range)
[1]. This suggests ideal experiments to be performed at
nM concentrations to obtain sensitive data modeling.
Considering the detection limit of current mass spec-
trometers operating in the ESI mode, we chose the
lowest concentration of antibody and antigenic peptide
that afford suitable mass spectra for accurate centroid
calculation for all data series. For the SC-Ab:PCS2a
interaction, the lowest concentrations used here were 41
and 20.5 nM, respectively, for the SC-Ab and the PCS2a
peptide.
Fitting the data for SC-Ab:PCS2a interaction, shown
as Figure 3, afforded a binding constant Ka of (3.4 0.3)
108 M1 (Kd  3.0  0.3 nM). The two fitted curves,
representing a 16-fold dilution from the lower dashed
curve to the upper solid curve, are well-separated only
in the “steep region” because the lowest macromolecule
concentration used for experiment is still one magni-
tude higher than the Kd value. Hence, we collected more
data points in the “steep region” to define better the
curve shape and to afford higher modeling sensitivity.
A 2-fold dilution (e.g., as we made in the case of
CaM · 4Ca2:-endorphin) is not appropriate here be-
cause it made the dilution series data almost overlapping
(data not shown) and lacked efficiency to provide a good
Figure 3. dPLIMSTEX fitting curves for SC-Ab:PCS2a system.
The concentration of antibody Fab regions (shown as [Fab(SC-Ab)])
is used in place of the antibody concentration in the modeling.
[Fab(SC-Ab)]total for the dashed line (- - - -) is 660 nM, whereas
[Fab(SC-Ab)]total for the solid line ____ is 41 nM. The error bars
shown for the data points represent the standard deviation from
duplicate independent experiments. The D0 mass is for the un-
bound peptide and is depicted as a line representing the asymp-
tote for the other curves.
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deviation between best fit and the experimental data,
thereby substantiating the reliability of the fitting results.
In addition, the binding stoichiometry was also as-
sessed by the dPLIMSTEX approach. IgG antibodies
frequently bind two antigens, each Fab region interacting
with one antigen molecule, but 1:1 antibody/antigen
binding stoichiometry was observed in other cases [2].
The dashed fitted curve in Figure 3, obtained when the
macromolecule concentration was more than two or-
ders of magnitude larger than Kd, is almost a “sharp-
break” curve that reveals the binding stoichiometry.
This break takes place when [PCS2a]total/[Fab(SC-Ab)]total
1. Note that we used the Fab concentration, and not the
antibody concentration, in the analysis and in the plot.
Given that there are two Fab regions per antibody, the
SC-Ab:PCS2a is a 1:2 binding system, as is normally the
case. This outcome also indicates that the two binding
events per antibody are independent.
The D1 from the modeling of SC-Ab:PCS2a is 2.3 
0.1, indicating that at least 5 backbone amide protons
(correcting for the % D2O in the exchange medium) of
the antigenic peptides are sequestered from HDX upon
binding and suggesting that at least five amino acids
constitute the epitope of the antigen peptide. When the
HDX kinetics curve of PCS2a was treated by two-group
modeling (Figure 4), we found an average chemical
exchange rate constant kex of free PCS2a at 0.69 s
1 for
58% exchangeable amide protons and 0.077 s1 for the
remaining 42% exchangeable amide protons. Compared
with the association rate kon of the SC-Ab:PCS2a com-
plex [these data will be published elsewhere], kex 
kon[M]. Therefore, the backbone amide hydrogens in the
peptide ligand are likely to undergo correlated exchange
Figure 4. The kinetic curve for H/D exchange of free PCS2a
peptide. All the data of deuterium uptake was normalized to the
highest average uptake value. The error bars shown for the data
points represent the standard deviation from duplicate indepen-
dent experiments.owing to the relatively slow association rate (i.e., HDX
occurs during the time following dissociation of the
complex and before the peptide can form a new com-
plex [41]. This can be considered as an inevitable “leak”
or loss of measured protected amide sites in the D1.
Consequently, the actual number of amide protons that
becomes sequestered upon complex formation is larger
than that calculated from D1. The influence of corre-
lated exchange and binding dynamics on the determi-
nation of Ka and D1 by dPLIMSTEX and the offset of
these parameters will be addressed in detail in future
work.
Conclusions
Compared with traditional PLIMSTEX, dPLIMSTEX has
several advantages for determining the affinity of an
antibody-peptide complex. The first is that dPLIMSTEX
monitors the peptide mass shift after HDX, which is less
subject to error because the D1 value is relatively large
fraction of the number of amides in the peptide. Second,
the peptide has high ionization efficiency, whereas at least
several micrograms [42] are required for each analysis of
antibodies to afford good mass spectra.
dPLIMSTEX appears to be a sensitive quantitative
method to study protein-peptide interactions. It deter-
mines the binding affinities and binding stoichiometry,
and estimates the extent of the interaction region of the
peptide ligand. The dilution series approach used in
dPLIMSTEX offers the opportunity to use a minimum
amount of macromolecule, especially for cases involv-
ing large proteins. The application of dPLIMSTEX to
antibody-antigen complexes offers the capability to
characterize the specificity and recognition motif of
antibodies in solution. More work using a series of
antigenic peptides is in progress.
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